The novel coronavirus pneumonia epidemic trend is difficult to predict because of the increasing number of mutation and the prevalence of variant strains in COVID-19. While the new crown vaccine has been effectively prevented and controlled, the demand for COVID-19's effective drugs has become increasingly urgent. What steps has been taken in COVID-19's effective drug use in China? What are the candidate "seed drugs"? Recently, ScienceDaily daily interviewed the relevant units on the progress of COVID-19's effective drug use. More than 20 months of emergency research and development, a variety of drugs are being used for treatment "There are a lot of antibodies in our body, but not all antibodies have antiviral effects. Our research goal is to select the strongest and best antiviral antibodies as antibody drugs to treat patients." Zhang Linqi, Professor of Tsinghua University School of medicine and director of the global health and infectious disease research center, told Science and technology daily, The team screened two highly active and highly complementary antibodies from hundreds of antibodies isolated from the blood of convalescent patients. In the clinical trials carried out at home and abroad, the antibody drug showed an excellent effect of reducing severe and mortality by 78%, and carried out clinical treatment for more than 700 infected people in the epidemic situations of Shenzhen, Guangzhou, Yunnan, Nanjing, Yangzhou, Putian, Xiamen, Zhengzhou and Heihe. According to the briefing, COVID-19's R & D mission was launched by the Ministry of science and technology in January 21, 2020. On February 16, 2020, a special drug R & D class of the scientific research team composed of the Ministry of science and technology, the health and Health Commission, the Ministry of industry and information technology, the national development and Reform Commission, the food and drug administration, the Bureau of traditional Chinese medicine and other departments was established to organize a national advantageous expert team to fully promote the R & D of effective drugs and therapeutic technologies around the needs of clinical treatment. According to the relevant person in charge, 53 emergency projects for scientific research in the clinical treatment and drug sector have been approved, involving about 315 million yuan of state allocated funds. At present, novel coronavirus pneumonia drugs developed by our R & D team have been used in clinical treatment. For example, the screening of two effective neutralizing antibody drugs brii-196 and brii-198 mentioned above has been involved in the treatment of more than 700 patients in China. In Beijing, a new neutralizing antibody has also been approved for sympathetic use in Beijing Ditan hospital. The drug is neutralizing antibody DXP604 developed by the Xie Xiaoliang team of Peking University and Daniel bio. Because of its 85% coincidence site, it makes human cells refuse to open the door to COVID-19. Internationally, the novel coronavirus pneumonia effective drug use also plays an important role in the epidemic line. Statistics show that the new generation of androgen receptor antagonist "prochloramide" under development in the pharmaceutical industry has been authorized for emergency use in Paraguay. The three clinical trials carried out in Brazil in the early stage preliminarily show that prochloramide can reduce the risk of death of severe patients by 78%. Multiple channels are promoted at the same time, and different links "block" the virus COVID-19 is a brand new virus. Which drug can fight its "seven inches"? What kind of "blocking" strategy can work? There is no final conclusion. To this end, in the process of COVID-19 drug research and development, China has deployed 3 technical routes. Relevant responsible person said, at present, COVID-19's effective drug research and development mainly revolves around the 3 technical routes of blocking viruses into cells, inhibiting virus replication and regulating the human immune system. The 3 technical routes have their own characteristics, and adopt different strategies to carry out "arresting" in different physiological links of COVID-19 infecting the human body. Taking the inhibition of virus replication as an example, by making a "low-quality" nucleotide to "cheat" the virus, making it use this "low-quality" material during its own replication, directly blocking replication or making the virus "self construction" become a "uncompleted project", we can successfully prevent virus replication. This strategy of small molecule drugs is used in nearly 50% of antiviral drugs. In addition, the selection of high-quality neutralizing antibodies is also a commonly used strategy. Through single cell technology, the researchers examined each of the convalescent people and found the best soldier to subdue COVID-19. More neutralizing antibodies should be found, and the cocktail therapy will have better effect on the mutants of COVID-19. Which drug is progressing the fastest? So, which drug has made the fastest progress? Is there a specific "timetable" for new crown specific drugs? Relevant data show that the fastest progress in antibody drugs is the neutralizing antibody combination therapy jointly developed by Tsinghua University, Shenzhen Third People's Hospital and Tengsheng Huachuang. It is reported that the National Institutes of Health (NIH) led the phase III clinical trial of the drug, which is being carried out in 7 countries such as the United States, Brazil and the Philippines. The research results are optimistic. The combined treatment of brii-196 and brii-198 can reduce hospitalization and mortality by 78%, and is most likely to take the lead in obtaining emergency use authorization in developed countries such as the United States. In China, the R & D team has submitted conditional listing application materials to the State Food and Drug Administration on October 9, and is expected to obtain approval (conditional) listing before the end of December. (outlook new era)